Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma (CBIO)
NASDAQ:CBIO
CBIO Stock Chart & Stats
$10.97
--
Market closed
$10.97
--
Day’s Range― - ―
52-Week Range$9.81 - $37.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)145.41K
Market Cap
$302.30M
Enterprise Value$7.94M
Total Cash (Recent Filing)$133.26M
Total Debt (Recent Filing)$1.74M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding27,556,767
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio-24.58
Price to Book (P/B)-139.86
Price to Sales (P/S)0.00
P/FCF Ratio-51.61
Enterprise Value/Market Cap0.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$28.20Price Target Upside157.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Design And Preclinical ValidationCR-001's VEGF x PD-1 bispecific design mirrors a leading comparator and shows cooperative binding and strong T-cell activation in preclinical studies, supporting potential meaningful anti-tumor activity.
Partnership And Strategic FundingPartnership and cross-licensing with Kelun Biotech, including upfront financing, extends development runway, enables parallel ex-China and China programs, and reduces near-term financing risk.
Regulatory And Clinical DevelopmentInvestigational New Drug clearance in the United States for CR-001 and a planned global Phase one/two ASCEND study across multiple tumor types increase prospects for early human safety and proof-of-concept data.
Bears Say
Cash Burn And Runway RiskHigh cash burn and a limited cash runway increase the likelihood of needing additional financing, which could dilute existing shareholders and pressure valuation.
Early-stage Clinical RiskPrograms remain early-stage and require clinical proof of benefit before therapeutic and commercial potential can be confirmed, creating substantial program risk for investors.
Operating Loss ConcernsA reported net loss highlights ongoing operating deficits that may heighten future financing needs and raise investor concern about near-term financial sustainability.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $9.81 and its highest was $37.00 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $302.30M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Apr 30, 2026 which is in 108 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on Nov 06, 2025. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.959 by $0.689.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 27,556,767 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.959. Following the earnings report the stock price went up 5.39%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.20 (157.06% Upside)
$28.20 (157.06% Upside)
Insider Transactions
Bought Shares
Worth $18.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.89%
12-Months-Change
Fundamentals
Return on Equity
-51.70%
Trailing 12-Months
Asset Growth
544.72%
Trailing 12-Months
Company Description
Crescent Biopharma
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$28.20
▲(157.06% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Orchestra BioMed Holdings
―
Fractyl Health, Inc.
―
Actuate Therapeutics, Inc.
―